Drug · DIN 02451190
UPTRAVI
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since March 17, 2020; first marketed April 21, 2016.
- Drug Identification Number (DIN)
- 02451190
- Company (DIN owner)
- Janssen Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Selexipag B01AC27
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SELEXIPAG | 1000 MCG |
Notices of Compliance
Health Canada approvals that name this DIN.
- November 23, 2018: NOC 21564New Drug Submission (NDS) · Merger - buyout
- January 20, 2016: NOC 17697New Drug Submission (NDS)
Other DINs named UPTRAVI
- DIN 02451158 · Marketed
- DIN 02451166 · Marketed
- DIN 02451174 · Marketed
- DIN 02451182 · Marketed
- DIN 02451204 · Marketed
- DIN 02451212 · Marketed
- DIN 02451220 · Marketed